Following this course, attendees will be able to:

• Describe the epidemiology of HF and implement strategies for the prevention of HF.
• Discuss the current scientific basis of HF from the perspectives of cardiovascular physiology, neurohormones, tissue factors, molecular biology, and genetics.
• Identify the findings of basic science research and current clinical trials and describe their implications for current and future HF therapy.
• Implement optimal guideline-based therapeutic options for HF, including pharmacologic agents, non-pharmacologic options, such as diet and exercise, and implantable devices.
• Manage comorbidities including hypertension, diabetes, depression, sleep apnea, and chemotherapy.
• Demonstrate awareness of psychosocial, economic, regulatory, and ethical issues in the treatment of patients with HF.
  Explain the patient, provider and system-related factors that contribute to racial and ethnic health disparities.
• Implement strategies for effective management of the patient with HF, incorporating the family, encouraging self- care, and employing the team approach.
• Outline strategies for transitioning patients from impatient to outpatient care and for reducing hospital readmissions.
• Engage in performance measurement and other site-based research.

Credits Available

CME 47.25; CNE:47.25 (including nursing pharmacology of 13.00)

CPE: 27.5

MOC: 7.75